# Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

> **NCT00612066** · PHASE2 · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Cushing's Disease

## Interventions

- **DRUG:** rosiglitazone maleate

## Key facts

- **NCT ID:** NCT00612066
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-04
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low accrual and funding term ended
- **Last updated:** 2020-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00612066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00612066, "Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00612066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*